01—Abstract
Summary
Summary of the 10-Q filed November 3, 2026. Cited figures are marked; the original filing is the authoritative source.
DuPont de Nemours, Inc. reported third-quarter 2026 net sales of $1.87 billiona, up 4 percent from $1.80 billion in the prior-year quarter, driven by a 5 percent increase in organic sales partially offset by a 1 percent unfavorable currency impact.
Income from continuing operations before income taxes rose to $279 millionb from $91 million, and net income available for common stockholders was $123 million, compared with a loss of $123 million a year earlier. Results were affected by the absence of prior-year transaction-related tax benefits and by discontinued operations, which posted a $45 million loss in the quarter. Operating EBITDA was $505 million for the quarter versus $465 million, with Healthcare & Water Technologies at $263 million and Diversified Industrials at $242 million.
For the nine months, net sales were $5.37 billionc, up 4 percent, and net income available for common stockholders was $427 million, compared with a loss of $653 million in the prior year. The Aramids Divestiture closed on April 1, 2026, for pre-tax cash proceeds of approximately $1.2 billion plus a $300 million note receivable and an equity interest valued at $325 million in Arclin. Cash and cash equivalents rose to $1.65 billion at September 30, 2026, from $715 million at year-end 2025, and long-term debt was $3.09 billion.
The company repurchased shares under its $2Bd Authorization, paid $243 million in dividends, and plans to repurchase $250 million more in the fourth quarter. The filing also details substantial legacy PFAS-related obligations.
The New Jersey settlement carries an aggregate payment of $875 million over 25 years, and the North Carolina settlement provides for $455 million over 15 years, with the company's share of the North Carolina liability at a net present value of $127 million. DuPont's indemnification liabilities total $728 million, and the company states it cannot estimate losses above amounts accrued, so these matters remain a key area of investor attention.
02—Key points
Key Highlights
- Third-quarter net sales of $1,868 million, up from $1,795 million, with organic sales up 5 percent and currency down 1 percent.
- Income from continuing operations before income taxes of $279 million in Q3 2026, compared with $91 million in Q3 2025; diluted EPS from continuing operations of $1.24 versus $0.70.
- Net income available for DuPont common stockholders of $427 million for the nine months, compared with a loss of $653 million in the prior-year period, largely reflecting discontinued operations results.
- Aramids Divestiture closed April 1, 2026, with a $378 million loss on sale recorded, including an $82 million gain in Q2 2026 from finalizing the disposal group's carrying value.
- Cash and cash equivalents of $1,652 million at September 30, 2026, up from $715 million at December 31, 2025, with no commercial paper outstanding.
- Share repurchases under the $2B Authorization included three accelerated share repurchase transactions and an open market repurchase, with an additional $250 million expected in the fourth quarter of 2026.
- PFAS-related settlements include a New Jersey settlement of $875 million payable over 25 years and a North Carolina settlement of $455 million payable over 15 years, with DuPont's share of the North Carolina liability at $127 million net present value.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed November 3, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $1.87B$1.79B | +4.1% |
| Cost of Revenue | $1.20B$1.18B | +1.9% |
| Gross Profit | $667.00M$616.00M | +8.3% |
| R&D Expenses | $42.00M$52.00M | −19.2% |
| SG&A Expenses | $260.00M$261.00M | −0.4% |
| Net Income | $123.00M-$123.00M | +200.0% |
| EPS (Basic) | $0.92$-0.88 | +204.5% |
| EPS (Diluted) | $0.91$-0.88 | +203.4% |
| Shares Outstanding (Basic) | 134.30M139.70M | −3.9% |
| Shares Outstanding (Diluted) | 135.10M140.00M | −3.5% |
05—Questions
Frequently Asked Questions
How did DuPont's sales and profitability change in the third quarter of 2026?
Net sales rose 4 percent to $1,868 million, driven by 5 percent organic growth, with Healthcare & Water Technologies up 4 percent organically and Diversified Industrials up 5 percent. Income from continuing operations before income taxes increased to $279 million from $91 million, and the effective tax rate was 38.7 percent, compared with a benefit rate of (12.1) percent in the prior-year quarter.
What were the financial terms of the Aramids Divestiture?
DuPont completed the sale of the Aramids business to a subsidiary of Arclin on April 1, 2026, receiving pre-tax cash proceeds of approximately $1.2 billion, subject to customary adjustments, a $300 million note receivable, and a non-controlling equity interest valued at $325 million. The transaction produced a total $378 million loss on sale, including an $82 million gain recognized in the second quarter of 2026.
What are the major PFAS-related financial obligations disclosed in the filing?
The New Jersey settlement provides for an aggregate cash payment of $875 million payable over 25 years, shared under the MOU, with a first payment of $71 million made on September 8, 2026. The North Carolina settlement provides for aggregate payments of $455 million over 15 years, with DuPont's net present value share at $127 million. The company also must provide $475 million of additional financial assurance for New Jersey remediation and $135 million for North Carolina, with DuPont responsible for 71 percent of each. The filing states that losses above the amounts accrued cannot currently be estimated.
How is DuPont returning capital to shareholders?
During the first nine months of 2026, DuPont paid $243 million in dividends and repurchased shares for $611 million including forward contracts. The company declared a fourth-quarter 2026 dividend of $0.60 per share and expects to repurchase $250 million of common stock in the fourth quarter under the $2B Authorization. The filing also notes a 1-for-3 reverse stock split effective June 24, 2026.
What is the state of DuPont's liquidity and debt position?
At September 30, 2026, cash and cash equivalents were $1,652 million and long-term debt was $3,094 million, with no commercial paper outstanding. Net working capital was $2,730 million and the current ratio was 2.36 to 1. The company held a $2 billion five-year revolving credit facility and a $750 million 364-day revolving credit facility, neither of which had drawdowns during the nine months. Credit ratings were BBB+ from S&P and Fitch and Baa1 from Moody's, all with stable outlooks.
06—Continue